Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis

Augusto Vaglio, Maria G. Catanoso, Lucia Spaggiari, Luca Magnani, Nicolò Pipitone, Pierluigi MacChioni, Lia Pulsatelli, Maria Nicastro, Gabriella Becchi, Domenico Corradi, Annibale Versari, Luigi Boiardi, Carlo Salvarani

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective Chronic periaortitis (CP) usually responds to glucocorticoids, but some patients have glucocorticoid-refractory disease or contraindications to glucocorticoid therapy. This study was undertaken to evaluate treatment with the anti-interleukin-6 receptor (anti-IL-6R) antibody tocilizumab in 2 patients with CP, one with refractory disease and the other with contraindications to glucocorticoids, and to assess IL-6 levels in an additional cohort of patients with CP. Methods Both patients were given intravenous tocilizumab (8 mg/kg) once every 4 weeks for 6 months. Serum IL-6 was measured in 22 patients with active CP and 16 healthy controls. Tissue IL-6 expression was assessed by confocal microscopy in biopsy specimens obtained from 6 patients with CP. Results In the first patient, whose disease was refractory to various immunosuppressive treatments, tocilizumab added to ongoing therapy with prednisone and methotrexate allowed prednisone withdrawal and induced resolution of symptoms, acute-phase reactant normalization, and reduction in 18F- fluorodeoxyglucose (18F-FDG) uptake on positron emission tomography. The patient experienced a relapse 7 months later and was successfully retreated with tocilizumab. In the second patient, who was unable to tolerate glucocorticoids because of psychiatric side effects, tocilizumab monotherapy induced sustained clinical and laboratory remission, 18F-FDG uptake disappearance, and CP shrinkage. Serum IL-6 levels were significantly higher in patients with active CP than in controls (P <0.0001), and IL-6 was abundantly expressed in biopsy specimens from CP patients, particularly by T cells, B cells, histiocytes, fibroblasts, and vascular smooth muscle cells. Conclusion Tocilizumab may be a therapeutic option for CP. The systemic and tissue up-regulation of IL-6 in CP, together with the clinical benefit of IL-6R blockade observed in our 2 patients, suggest that IL-6 may contribute to CP pathogenesis.

Original languageEnglish
Pages (from-to)2469-2475
Number of pages7
JournalArthritis and Rheumatism
Volume65
Issue number9
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Retroperitoneal Fibrosis
Interleukin-6
Glucocorticoids
Therapeutics
Fluorodeoxyglucose F18
Prednisone
Biopsy
Interleukin-6 Receptors
Histiocytes
Acute-Phase Proteins
Immunosuppressive Agents
Serum
Vascular Smooth Muscle
Confocal Microscopy
Methotrexate
Positron-Emission Tomography
Smooth Muscle Myocytes
Psychiatry
tocilizumab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Vaglio, A., Catanoso, M. G., Spaggiari, L., Magnani, L., Pipitone, N., MacChioni, P., ... Salvarani, C. (2013). Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis and Rheumatism, 65(9), 2469-2475. https://doi.org/10.1002/art.38032

Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. / Vaglio, Augusto; Catanoso, Maria G.; Spaggiari, Lucia; Magnani, Luca; Pipitone, Nicolò; MacChioni, Pierluigi; Pulsatelli, Lia; Nicastro, Maria; Becchi, Gabriella; Corradi, Domenico; Versari, Annibale; Boiardi, Luigi; Salvarani, Carlo.

In: Arthritis and Rheumatism, Vol. 65, No. 9, 08.2013, p. 2469-2475.

Research output: Contribution to journalArticle

Vaglio, A, Catanoso, MG, Spaggiari, L, Magnani, L, Pipitone, N, MacChioni, P, Pulsatelli, L, Nicastro, M, Becchi, G, Corradi, D, Versari, A, Boiardi, L & Salvarani, C 2013, 'Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis', Arthritis and Rheumatism, vol. 65, no. 9, pp. 2469-2475. https://doi.org/10.1002/art.38032
Vaglio A, Catanoso MG, Spaggiari L, Magnani L, Pipitone N, MacChioni P et al. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis and Rheumatism. 2013 Aug;65(9):2469-2475. https://doi.org/10.1002/art.38032
Vaglio, Augusto ; Catanoso, Maria G. ; Spaggiari, Lucia ; Magnani, Luca ; Pipitone, Nicolò ; MacChioni, Pierluigi ; Pulsatelli, Lia ; Nicastro, Maria ; Becchi, Gabriella ; Corradi, Domenico ; Versari, Annibale ; Boiardi, Luigi ; Salvarani, Carlo. / Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. In: Arthritis and Rheumatism. 2013 ; Vol. 65, No. 9. pp. 2469-2475.
@article{9137b11385b14beda4d8e32b184764f1,
title = "Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis",
abstract = "Objective Chronic periaortitis (CP) usually responds to glucocorticoids, but some patients have glucocorticoid-refractory disease or contraindications to glucocorticoid therapy. This study was undertaken to evaluate treatment with the anti-interleukin-6 receptor (anti-IL-6R) antibody tocilizumab in 2 patients with CP, one with refractory disease and the other with contraindications to glucocorticoids, and to assess IL-6 levels in an additional cohort of patients with CP. Methods Both patients were given intravenous tocilizumab (8 mg/kg) once every 4 weeks for 6 months. Serum IL-6 was measured in 22 patients with active CP and 16 healthy controls. Tissue IL-6 expression was assessed by confocal microscopy in biopsy specimens obtained from 6 patients with CP. Results In the first patient, whose disease was refractory to various immunosuppressive treatments, tocilizumab added to ongoing therapy with prednisone and methotrexate allowed prednisone withdrawal and induced resolution of symptoms, acute-phase reactant normalization, and reduction in 18F- fluorodeoxyglucose (18F-FDG) uptake on positron emission tomography. The patient experienced a relapse 7 months later and was successfully retreated with tocilizumab. In the second patient, who was unable to tolerate glucocorticoids because of psychiatric side effects, tocilizumab monotherapy induced sustained clinical and laboratory remission, 18F-FDG uptake disappearance, and CP shrinkage. Serum IL-6 levels were significantly higher in patients with active CP than in controls (P <0.0001), and IL-6 was abundantly expressed in biopsy specimens from CP patients, particularly by T cells, B cells, histiocytes, fibroblasts, and vascular smooth muscle cells. Conclusion Tocilizumab may be a therapeutic option for CP. The systemic and tissue up-regulation of IL-6 in CP, together with the clinical benefit of IL-6R blockade observed in our 2 patients, suggest that IL-6 may contribute to CP pathogenesis.",
author = "Augusto Vaglio and Catanoso, {Maria G.} and Lucia Spaggiari and Luca Magnani and Nicol{\`o} Pipitone and Pierluigi MacChioni and Lia Pulsatelli and Maria Nicastro and Gabriella Becchi and Domenico Corradi and Annibale Versari and Luigi Boiardi and Carlo Salvarani",
year = "2013",
month = "8",
doi = "10.1002/art.38032",
language = "English",
volume = "65",
pages = "2469--2475",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis

AU - Vaglio, Augusto

AU - Catanoso, Maria G.

AU - Spaggiari, Lucia

AU - Magnani, Luca

AU - Pipitone, Nicolò

AU - MacChioni, Pierluigi

AU - Pulsatelli, Lia

AU - Nicastro, Maria

AU - Becchi, Gabriella

AU - Corradi, Domenico

AU - Versari, Annibale

AU - Boiardi, Luigi

AU - Salvarani, Carlo

PY - 2013/8

Y1 - 2013/8

N2 - Objective Chronic periaortitis (CP) usually responds to glucocorticoids, but some patients have glucocorticoid-refractory disease or contraindications to glucocorticoid therapy. This study was undertaken to evaluate treatment with the anti-interleukin-6 receptor (anti-IL-6R) antibody tocilizumab in 2 patients with CP, one with refractory disease and the other with contraindications to glucocorticoids, and to assess IL-6 levels in an additional cohort of patients with CP. Methods Both patients were given intravenous tocilizumab (8 mg/kg) once every 4 weeks for 6 months. Serum IL-6 was measured in 22 patients with active CP and 16 healthy controls. Tissue IL-6 expression was assessed by confocal microscopy in biopsy specimens obtained from 6 patients with CP. Results In the first patient, whose disease was refractory to various immunosuppressive treatments, tocilizumab added to ongoing therapy with prednisone and methotrexate allowed prednisone withdrawal and induced resolution of symptoms, acute-phase reactant normalization, and reduction in 18F- fluorodeoxyglucose (18F-FDG) uptake on positron emission tomography. The patient experienced a relapse 7 months later and was successfully retreated with tocilizumab. In the second patient, who was unable to tolerate glucocorticoids because of psychiatric side effects, tocilizumab monotherapy induced sustained clinical and laboratory remission, 18F-FDG uptake disappearance, and CP shrinkage. Serum IL-6 levels were significantly higher in patients with active CP than in controls (P <0.0001), and IL-6 was abundantly expressed in biopsy specimens from CP patients, particularly by T cells, B cells, histiocytes, fibroblasts, and vascular smooth muscle cells. Conclusion Tocilizumab may be a therapeutic option for CP. The systemic and tissue up-regulation of IL-6 in CP, together with the clinical benefit of IL-6R blockade observed in our 2 patients, suggest that IL-6 may contribute to CP pathogenesis.

AB - Objective Chronic periaortitis (CP) usually responds to glucocorticoids, but some patients have glucocorticoid-refractory disease or contraindications to glucocorticoid therapy. This study was undertaken to evaluate treatment with the anti-interleukin-6 receptor (anti-IL-6R) antibody tocilizumab in 2 patients with CP, one with refractory disease and the other with contraindications to glucocorticoids, and to assess IL-6 levels in an additional cohort of patients with CP. Methods Both patients were given intravenous tocilizumab (8 mg/kg) once every 4 weeks for 6 months. Serum IL-6 was measured in 22 patients with active CP and 16 healthy controls. Tissue IL-6 expression was assessed by confocal microscopy in biopsy specimens obtained from 6 patients with CP. Results In the first patient, whose disease was refractory to various immunosuppressive treatments, tocilizumab added to ongoing therapy with prednisone and methotrexate allowed prednisone withdrawal and induced resolution of symptoms, acute-phase reactant normalization, and reduction in 18F- fluorodeoxyglucose (18F-FDG) uptake on positron emission tomography. The patient experienced a relapse 7 months later and was successfully retreated with tocilizumab. In the second patient, who was unable to tolerate glucocorticoids because of psychiatric side effects, tocilizumab monotherapy induced sustained clinical and laboratory remission, 18F-FDG uptake disappearance, and CP shrinkage. Serum IL-6 levels were significantly higher in patients with active CP than in controls (P <0.0001), and IL-6 was abundantly expressed in biopsy specimens from CP patients, particularly by T cells, B cells, histiocytes, fibroblasts, and vascular smooth muscle cells. Conclusion Tocilizumab may be a therapeutic option for CP. The systemic and tissue up-regulation of IL-6 in CP, together with the clinical benefit of IL-6R blockade observed in our 2 patients, suggest that IL-6 may contribute to CP pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84883260218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883260218&partnerID=8YFLogxK

U2 - 10.1002/art.38032

DO - 10.1002/art.38032

M3 - Article

C2 - 23740665

AN - SCOPUS:84883260218

VL - 65

SP - 2469

EP - 2475

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 9

ER -